Editas Medicine Inc
EDITHealthcare|Biotechnology|USA
$3.26
-0.03 (-0.76%)
Tangible Book
$0.05
Financials
Financial Snapshot
Market Cap
$500.3M
Enterprise Value
$106.4M
Revenue (TTM)
$38.7M
Net Income (TTM)
$-109.0M
Cash & Equivalents
—
Net Cash/Share
$-0.22
Free Cash Flow (TTM)
$-141.1M
Operating CF (TTM)
$-140.5M
Debt/Equity
3.92
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$35.1M
Monthly Burn
$11.7M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $185.3M | $329.1M | $369.0M | $457.1M | $402.1M | $499.8M | $344.3M | $323.1M | $269.9M | $146.6M | $123.6M | |
| Operating Cash Flow | $-50.2M | $-9.4M | $-45.7M | $-40.7M | $-179.8M | $-163.8M | $-177.3M | $-132.2M | $-210.3M | $-165.2M | $-140.5M | |
| Free Cash Flow | $-53.7M | $-11.5M | $-50.5M | $-46.8M | $-187.0M | $-171.8M | $-181.5M | $-136.9M | $-219.1M | $-165.8M | $-141.1M | |
| Capital Expenditure | $-3.5M | $-2.1M | $-4.8M | $-6.2M | $-7.2M | $-8.0M | $-4.1M | $-4.7M | $-8.8M | $-607.0K | $-585.0K | |
| Financing Cash Flow | $97.2M | $154.5M | $86.9M | $131.8M | $224.1M | $282.1M | $1.3M | $118.0M | $56.0M | $40.5M | $41.9M |
R&D Spending
R&D (TTM)
$81.0M
R&D Intensity
209.2%
R&D Growth YoY
-10.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M | $38.7M | |
| R&D Expense | $57.0M | $83.2M | $90.7M | $96.9M | $158.0M | $142.5M | $175.0M | $177.7M | $199.2M | $90.0M | $81.0M | |
| R&D % of Revenue | 941.3% | 605.8% | 283.9% | 472.0% | 174.1% | 557.9% | 887.6% | 227.4% | 616.6% | 222.0% | 209.2% | |
| SG&A | $46.3M | $50.5M | $55.0M | $64.6M | $67.6M | $76.2M | $70.7M | $69.7M | $72.0M | $49.9M | $46.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M | $38.7M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M | $38.7M | |
| R&D | $57.0M | $83.2M | $90.7M | $96.9M | $158.0M | $142.5M | $175.0M | $177.7M | $199.2M | $90.0M | $81.0M | |
| SG&A | $46.3M | $50.5M | $55.0M | $64.6M | $67.6M | $76.2M | $70.7M | $69.7M | $72.0M | $49.9M | $46.8M | |
| Operating Income | $-97.2M | $-119.9M | $-113.7M | $-140.9M | $-134.8M | $-193.1M | $-225.9M | $-169.2M | $-238.9M | $-99.3M | $-89.0M | |
| Interest Expense | $62.0K | $-978.0K | $3.4M | $7.3M | $0.00 | $0.00 | $0.00 | $0.00 | $-2.2M | $-6.2M | $-5.0M | |
| Pretax Income | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-116.0M | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M | $-109.0M | |
| Net Income | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-116.0M | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M | $-109.0M | |
| EPS (Diluted) | -3.02 | -2.98 | -2.33 | -2.68 | -1.98 | -2.85 | -3.21 | -2.02 | -2.88 | -1.80 | -1.23 | |
| EBITDA | $-96.0M | $-116.7M | $-110.5M | $-138.1M | $-130.9M | $-188.1M | $-219.6M | $-163.1M | $-229.1M | $-148.6M | $-100.1M | |
| Shares Out. (M) | 32.22 | 40.32 | 47.10 | 49.98 | 58.61 | 67.62 | 68.67 | 75.97 | 82.34 | 88.75 | 97.88 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $185.3M | $146.6M | $134.8M | $238.2M | $139.7M | $203.5M | $141.5M | $123.7M | $131.5M | $146.6M | $123.6M | |
| Marketable Securities | $0.00 | $182.5M | $234.2M | $219.0M | $262.4M | $296.3M | $202.8M | $199.5M | $138.4M | $0.00 | $0.00 | |
| Total Current Assets | $187.2M | $332.2M | $374.8M | $463.8M | $419.1M | $507.3M | $356.8M | $340.8M | $289.3M | $163.9M | $128.1M | |
| Total Assets | $229.2M | $373.3M | $420.4M | $508.9M | $572.6M | $677.5M | $514.3M | $499.2M | $341.6M | $186.5M | $149.3M | |
| Total Current Liabilities | $33.1M | $36.7M | $35.9M | $60.0M | $58.2M | $46.9M | $60.1M | $63.2M | $77.2M | $46.2M | $39.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $94.6M | $165.2M | $184.2M | $246.4M | $179.0M | $123.8M | $153.6M | $150.1M | $207.3M | $159.2M | $144.9M | |
| Stockholders' Equity | $134.6M | $208.1M | $236.2M | $262.4M | $393.6M | $553.6M | $360.7M | $349.1M | $134.3M | $27.3M | $4.4M | |
| Retained Earnings | $-185.5M | $-305.9M | $-416.3M | $-549.2M | $-665.2M | $-857.7M | $-1.08B | $-1.23B | $-1.47B | $-1.63B | $-1.65B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-50.2M | $-9.4M | $-45.7M | $-40.7M | $-179.8M | $-163.8M | $-177.3M | $-132.2M | $-210.3M | $-165.2M | $-140.5M | |
| Capital Expenditure | $-3.5M | $-2.1M | $-4.8M | $-6.2M | $-7.2M | $-8.0M | $-4.1M | $-4.7M | $-8.8M | $-607.0K | $-585.0K | |
| Free Cash Flow | $-53.7M | $-11.5M | $-50.5M | $-46.8M | $-187.0M | $-171.8M | $-181.5M | $-136.9M | $-219.1M | $-165.8M | $-141.1M | |
| Investing Cash Flow | $-3.5M | $-183.8M | $-53.1M | $12.3M | $-140.5M | $-54.5M | $114.1M | $-3.7M | $162.1M | $138.7M | $82.3M | |
| Financing Cash Flow | $97.2M | $154.5M | $86.9M | $131.8M | $224.1M | $282.1M | $1.3M | $118.0M | $56.0M | $40.5M | $41.9M | |
| Issuance of Stock | $97.5M | $154.1M | $76.8M | $116.3M | $203.7M | $249.5M | $0.00 | $117.1M | $0.00 | $42.8M | $41.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $-560.0K | $-1.4M | $-857.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $16.9M | $23.4M | $26.6M | $27.2M | $23.2M | $43.4M | $29.3M | $19.8M | $21.4M | $10.0M | $9.1M | |
| Net Change in Cash | $43.4M | $-38.7M | $-11.9M | $103.4M | $-96.2M | $63.8M | $-62.0M | $-17.9M | $7.9M | $13.9M | $-16.3M |
Dilution Tracker
Shares outstanding grew 44.8% over 5 years — significant dilution
Shares Outstanding
98M
5-Year Share Growth
+44.8%
Stock Issuance (TTM)
$41.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 32.22 | 40.32 | 47.10 | 49.98 | 58.61 | 67.62 | 68.67 | 75.97 | 82.34 | 88.75 | 97.88 | |
| YoY Change % | — | 25.2% | 16.8% | 6.1% | 17.3% | 15.4% | 1.5% | 10.6% | 8.4% | 7.8% | 10.3% | |
| Stock Issuance | $97.5M | $154.1M | $76.8M | $116.3M | $203.7M | $249.5M | $0.00 | $117.1M | $0.00 | $42.8M | $41.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $16.9M | $23.4M | $26.6M | $27.2M | $23.2M | $43.4M | $29.3M | $19.8M | $21.4M | $10.0M | $9.1M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | -1605.6% | -873.6% | -356.1% | -686.4% | -148.6% | -756.1% | -1146.3% | -216.6% | -739.4% | -245.2% | -230.1% | |
| Net Margin % | -1605.5% | -876.5% | -344.3% | -651.4% | -127.8% | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% | -281.6% | |
| EBITDA Margin % | -1586.7% | -849.8% | -345.9% | -672.6% | -144.3% | -736.3% | -1114.1% | -208.8% | -709.0% | -366.8% | -258.7% | |
| FCF Margin % | -887.8% | -83.6% | -158.0% | -228.1% | -206.1% | -672.5% | -920.6% | -175.2% | -678.1% | -409.3% | -364.6% | |
| ROE % | -377.5% | -70.2% | -49.5% | -53.6% | -35.4% | -40.6% | -48.2% | -43.2% | -98.1% | -198.1% | -429.8% | |
| ROA % | -51.3% | -39.9% | -27.7% | -28.8% | -21.4% | -30.8% | -37.0% | -30.2% | -56.4% | -60.6% | -53.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S7.97
Historical1.60 / 35.53 / 163.33
Industry Med.9.49
P/B72.44
Historical0.57 / 4.40 / 81.11
Industry Med.2.93
EV/EBITDA-3.94
Historical-45.49 / -4.10 / 0.60
Industry Med.13.02
EV/Revenue10.18
Historical-4.15 / 24.82 / 134.69
Industry Med.8.59
P/FCF—
Historical20.87 / 53.68 / 206.24
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$0.05
Median P/S Value
$15.41
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | 86.33 | 90.38 | 33.55 | 72.04 | 45.29 | 70.24 | 30.91 | 9.85 | 3.24 | 4.49 | 7.97 | |
| PB Ratio | 4.32 | 6.57 | 4.70 | 6.13 | 11.14 | 3.28 | 1.69 | 2.37 | 0.78 | 7.35 | 72.44 | |
| EV/EBITDA | -4.59 | -9.25 | -6.99 | -8.56 | -30.64 | -7.14 | -1.41 | -3.32 | 0.57 | -0.49 | -3.94 | |
| EV/Revenue | 72.87 | 78.64 | 24.20 | 57.54 | 44.20 | 52.59 | 15.74 | 6.93 | -4.02 | 1.78 | 10.18 |
Analyst Estimates & Quality
Altman Z-Score
-14.76
Distress
Piotroski F-Score
3
Weak
Beneish M-Score
2.83
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $14.97M | $14.79M | $7.17M |
| Net Income | $-107.55M | $-120.27M | $-138.93M |
| EPS | -1.00 | -0.97 | -1.05 |
| Book Value per Share | -1.22 | 0.00 | 0.00 |
| Operating Cash Flow per Share | -0.92 | -0.76 | -1.55 |
| Operating CF | $-89.56M | $-74.39M | $-151.71M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Business of developing and commercializing genome editing technology | $40.5M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $40.5M |